Silk Road Medical, Inc. operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization. Its products includes ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and initiate temporary blood flow reversal; ENROUTE Transcarotid Stent System, a self-expanding, self-tapering stent; ENHANCE Transcarotid Peripheral Access Kit for use in gaining initial access to the common carotid artery; and ENROUTE 0.014 Guidewire for navigating and crossing the target lesion for delivery of interventional devices. The company was incorporated in 2007 and is headquartered in Sunnyvale, California.
IPO Year: 2019
Exchange: NASDAQ
Website: silkroadmed.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/11/2024 | Buy → Sell | Argus | |
| 3/7/2024 | $24.00 | Hold → Buy | Argus |
| 1/19/2024 | $9.00 → $20.00 | Hold → Buy | Stifel |
| 1/3/2024 | $20.00 | Buy | Lake Street |
| 10/24/2023 | Underperform → Peer Perform | Wolfe Research | |
| 10/11/2023 | $54.00 → $14.00 | Buy → Neutral | B. Riley Securities |
| 10/11/2023 | Buy → Neutral | CL King | |
| 10/11/2023 | $45.00 → $12.00 | Buy → Hold | Stifel |
| 10/11/2023 | $35.00 → $8.00 | Buy → Sell | Citigroup |
| 9/21/2023 | Buy → Hold | Argus |